OBJECTIVE: To explore whether antiplatelet (AP) agent therapy increased intracranial
hemorrhage (ICH) incidence and reduced ischemic stroke recurrence. METHODS: A single …

Objective To investigate the usage of antiplatelet drugs (APD) therapy in ischemic stroke
with a history of intracranial hemorrhage (ICH) and impact of APD therapy in recurrences of …

Boysen G (University of Copenhagen, Copenhagen, Denmark). Bleeding complications in
secondary stroke prevention by antiplatelet therapy: a benefit–risk analysis (Review). J …

Background and Purpose—Antiplatelet medicines are commonly perceived as
contraindicated after intracerebral hemorrhage (ICH). Many ICH patients have or will have …

Objective Antiplatelet medications are increasingly being used for primary and secondary
prevention of ischemic attacks owing to the increasing prevalence of ischemic stroke …

This focused update about antiplatelet agents to reduce the high risk of major adverse
cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral …

Stroke is the second cause of death worldwide and one of the leading cause of disability.
Due to the high rate of recurrence, in high risk-patients (eg patients affected by …

Background: Survivors of intracerebral hemorrhage are at risk for recurrent intracerebral
hemorrhage and ischemic cardiovascular and cerebrovascular disease. Objective: To …

Antiplatelet (AP) drugs play a major role in stroke prevention. Aspirin (50-1300 mg),
ticlopidine (500 mg), clopidogrel (75 mg) and dipyridamole (400 mg) are effective in …

Background and Purpose—Although the use of antiplatelet therapy (APT) is associated with
the risk of intracerebral hemorrhage (ICH), there are limited data on prestroke APT and …